The declining impact of the US National Institutes of Health on cancer patenting

US Patent and Trademark Office data show a slowing of NIH-supported cancer patent innovation since 1995, amid criticism of an incremental rather than a high-risk, high-reward funding strategy.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1
Fig. 2


  1. 1.

    Kolata, G. Grant system leads cancer researchers to play it safe. The New York Times (27 June 2009).

  2. 2.

    Drazen, J. M. & Ingelfinger, J. R. N. Engl. J. Med. 349, 2259–2261 (2003).

  3. 3.

    Fang, F. C. & Casadevall, A. MBio 7, e00422–16 (2016).

  4. 4.

    Nicholson, J. M. & Ioannidis, J. P. A. Nature 492, 34–36 (2012).

  5. 5.

    Salzberg, S. L. Nature 493, 26 (2013).

  6. 6.

    Mervis, J. Science 338, 1274 (2012).

  7. 7.

    President’s Council of Advisors on Science and Technology. Transformation and Opportunity: The Future of the US Research Enterprise. (2012).

  8. 8.

    Frumkin, J. & Myers, A. USPTO Cancer Moonshot patent data. (19 August 2016).

  9. 9.

    Chartrand, S. Patents: a coming court test on whether corn seed and mathematical instructions have similar status. The New York Times (12 March 2001).

  10. 10.

    Lawrence, S. Nat. Biotechnol. 22, 930–931 (2004).

  11. 11.

    USPTO. Utility examination guidelines (USPTO, 2001).

  12. 12.

    Trajtenberg, M. Rand J. Econ. 21, 172–187 (1990).

Download references


The author thanks S. Bechtold, B. Sampat, L. Wier and the participants of the American Society of Law, Medicine & Ethics bioip Faculty Workshop, Atlanta, and the Inaugural Wiet Life Science Law Scholars Conference, Chicago, for comments and suggestions.

Author information

Correspondence to Raphael Zingg.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark